ATE233095T1 - Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt - Google Patents

Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt

Info

Publication number
ATE233095T1
ATE233095T1 AT95929805T AT95929805T ATE233095T1 AT E233095 T1 ATE233095 T1 AT E233095T1 AT 95929805 T AT95929805 T AT 95929805T AT 95929805 T AT95929805 T AT 95929805T AT E233095 T1 ATE233095 T1 AT E233095T1
Authority
AT
Austria
Prior art keywords
rapamycin
preparation containing
combination preparation
xanthine derivative
containing cyclosporin
Prior art date
Application number
AT95929805T
Other languages
English (en)
Inventor
Martin Schoenharting
Ulrich Gebert
Mark Waer
Original Assignee
Hoechst Ag
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Univ Leuven Kath filed Critical Hoechst Ag
Application granted granted Critical
Publication of ATE233095T1 publication Critical patent/ATE233095T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT95929805T 1994-08-25 1995-08-07 Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt ATE233095T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4430127A DE4430127A1 (de) 1994-08-25 1994-08-25 Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
PCT/EP1995/003126 WO1996005854A2 (en) 1994-08-25 1995-08-07 Combination preparation, containing cyclosporin a or fk506 or rapamycin and a xanthine derivative

Publications (1)

Publication Number Publication Date
ATE233095T1 true ATE233095T1 (de) 2003-03-15

Family

ID=6526514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929805T ATE233095T1 (de) 1994-08-25 1995-08-07 Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt

Country Status (9)

Country Link
US (2) US6046328A (de)
EP (1) EP0797448B1 (de)
CN (1) CN1096859C (de)
AT (1) ATE233095T1 (de)
AU (1) AU714129B2 (de)
CA (1) CA2199949A1 (de)
DE (2) DE4430127A1 (de)
MX (1) MX9702181A (de)
WO (1) WO1996005854A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087849A2 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf- alpha signaling
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US7687530B2 (en) * 2002-11-21 2010-03-30 Genzyme Corporation Inhibition of chronic tissue transplant rejection
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
WO2007041506A1 (en) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Purine formulations and methods for managing disorders
EP1787645A1 (de) * 2005-11-18 2007-05-23 Institut Curie Neue Krebsbehandlung durch Modulierung des Calcineurin- und/oder Calcineurin/NFAT-Weg
EP2839837B1 (de) * 2006-09-15 2019-05-08 Children's Hospital of Eastern Ontario Research Institute Inc. Onkolytisches farmington rhabdovirus
ES2393814T3 (es) * 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
BRPI0908107A2 (pt) * 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9328113B2 (en) 2012-04-13 2016-05-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2705856A1 (de) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Verbindungen zur Behandlung von neurodegenerativen Erkrankungen
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
WO2022042390A1 (zh) * 2020-08-25 2022-03-03 广东众生睿创生物科技有限公司 羟基嘌呤类化合物用于治疗皮肤疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007566A2 (en) * 1990-11-01 1992-05-14 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
WO1993017684A2 (en) * 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds

Also Published As

Publication number Publication date
AU714129B2 (en) 1999-12-16
CN1162919A (zh) 1997-10-22
AU3342895A (en) 1996-03-14
US6046328A (en) 2000-04-04
WO1996005854A3 (en) 1996-04-11
EP0797448A2 (de) 1997-10-01
MX9702181A (es) 1997-06-28
CN1096859C (zh) 2002-12-25
CA2199949A1 (en) 1996-02-29
DE4430127A1 (de) 1996-03-14
WO1996005854A2 (en) 1996-02-29
US6432968B1 (en) 2002-08-13
DE69529769D1 (de) 2003-04-03
EP0797448B1 (de) 2003-02-26

Similar Documents

Publication Publication Date Title
ATE233095T1 (de) Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt
EP1149581A3 (de) Verwendung von Rapamycinderivaten zur Behandlung von Gefässerkrankungen und Xenotransplantationen
EP0650356A4 (de) Rapamycinderivate.
EP0650489A4 (de) Rapamycinderivate.
DK0839126T3 (da) Fremgangsmåde til fremstilling af organiske nitrogenforbindelser, specielle organiske nitrogenforbindelser og blandinger af sådanne forbindelser samt deres anvendelse som brændstof- og smøremiddeladditiver
GB2247017B (en) Rapamycin derivatives
DE69103720D1 (de) Zündmittelzusammensetzung für Gasaufblasvorrichtung.
ZA931490B (en) Novel rapamycin 42-sulfonates and 42-(n-carboalkoxy) sulfamates useful as immunosuppressive agents
EP0662935A4 (de) Gasgenerator.
HU910659D0 (en) Ignition unit for kitchen functioning with liquified gas
EP0661253A3 (de) Gaserzeugende Zusammensetzungen, wobei als Brennstoff Dicyanamid-Salze benutzt werden.
FR2665726B1 (fr) Soufflante de turbomachine a amortisseur dynamique a cames.
EP0634608A3 (de) Doppelring-Gasbrenner.
EP0369685A3 (de) Fluoxetin-Analogon
ES2196824T3 (es) Derivado de triazolo-piridazina sustituido y composiciones farmaceuticas fabricadas con el mismo.
EP0661972A4 (de) Verwendung von spiperon und spiperonderivaten als immunsuppressive wirkstoffe.
BG99638A (en) Derivatives of xanthine as diuretic form
DE69417584D1 (de) 7-[carboxyalkyl oder alkenyl]-6-[alkyl oder alkenyl] 3-oxo-2,4-dioxobicyclo-[3.2.1]octan und dessen derivate
AU7419694A (en) Support grid for sitting or lying furniture, as well as support elements for the support grid
EP0660045A3 (de) Taschenfeuerzeug.
HUP9900601A2 (hu) Benzopirán-származékok allograftkilökődés megelőzésére
GB2315216B (en) Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
NL193734B (nl) Combinatie van een kaars en kaarshouder, en kaars en kaarshouder geschikt voor de combinatie.
AU6580500A (en) Igniters for gas generators
EP0656510A3 (de) Taschenfeuerzeug.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0797448

Country of ref document: EP

REN Ceased due to non-payment of the annual fee